Brought to you by 
Ligand, TAP develop androgen receptor modulators; concluded
11 Mar 2008
Executive Summary
Ligand Pharmaceuticals (gene transcription technology) and TAP Pharmaceutical Products (the US joint venture of Takeda Chemical and Abbott Laboratories) will jointly discover and develop selective androgen receptor modulators (SARMs) for treating diseases in the areas of urology, gynecology, and endocrinology.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Concluded
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ligand, TAP develop androgen receptor modulators; concluded
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice